U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Go back to U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 246.81 -0.76 (0.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $247.57 | 52 Week High | $160.00 | |||
| Open | $246.00 | 52 Week Low | $95.80 | |||
| Day High | $249.00 | P/E | 45.88 | |||
| Day Low | $244.75 | EPS | $5.38 | |||
| Volume | 321,870 | |||||
